Conditions: Ovarian Clear Cell Adenocarcinoma; Platinum-Sensitive Ovarian Carcinoma; Recurrent Endometrial Serous Adenocarcinoma; Recurrent Fallopian Tube Carcinoma; Recurrent Fallopian Tube Endometrioid Adenocarcinoma; Recurrent Fallopian Tube Serous Adenocarcinoma; Recurrent Ovarian Carcinoma; Recurrent Ovarian Clear Cell Adenocarcinoma; Recurrent Ovarian Endometrioid Adenocarcinoma; Recurrent Ovarian Serous Adenocarcinoma; Recurrent Platinum-Resistant Ovarian Carcinoma; Recurrent Primary Peritoneal Carcinoma; Recurrent Primary Peritoneal Clear Cell Adenocarcinoma; Recurrent Primary Peritoneal Endometrioid Adenocarcinoma; Recurrent Primary Peritoneal Serous Adenocarcinoma
Interventions: Biological: Anti-CD40 Agonist Monoclonal Antibody CDX-1140; Biological: Bevacizumab; Biological: Pembrolizumab; Other: Quality-of-Life Assessment; Other: Questionnaire Administration
Sponsors: Roswell Park Cancer Institute; National Cancer Institute (NCI); Merck Sharp & Dohme LLC; Celldex Therapeutics
Not yet **RECRUITING NOW**
Source: View full study details on ClinicalTrials.gov
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
